With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
The Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant Key Takeaways: AstraZeneca…
Recent Articles
RELATED ARTICLES
-
AstraZeneca could face limited fallout from Chinese tax probe
AZN.US -
CARsgen seeks cell therapy breakthrough but stays in the red for now
2171.HK
-
NEWS WRAP: AstraZeneca China president assisting in investigation
AZN.US
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
